Nucleic acid testing (NAT) of organ donors

Is the 'best' test the right test? a consensus conference report

A. Humar, Michele I Morris, E. Blumberg, R. Freeman, J. Preiksaitis, B. Kiberd, E. Schweitzer, S. Ganz, A. Caliendo, J. P. Orlowski, B. Wilson, C. Kotton, M. Michaels, S. Kleinman, S. Geier, B. Murphy, M. Green, M. Levi, G. Knoll, D. Segev & 10 others S. Brubaker, R. Hasz, D. J. Lebovitz, D. Mulligan, K. O'Connor, T. Pruett, M. Mozes, I. Lee, F. Delmonico, S. Fischer

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Nucleic acid testing (NAT) for HIV, HBV and HCV shortens the time between infection and detection by available testing. A group of experts was selected to develop recommendations for the use of NAT in the HIV/HBV/HCV screening of potential organ donors. The rapid turnaround times needed for donor testing and the risk of death while awaiting transplantation make organ donor screening different from screening blood-or tissue donors. In donors with no identified risk factors, there is insufficient evidence to recommend routine NAT, as the benefits of NAT may not outweigh the disadvantages of NAT especially when false-positive results can lead to loss of donor organs. For donors with identified behavioral risk factors, NAT should be considered to reduce the risk of transmission and increase organ utilization. Informed consent balancing the risks of donor-derived infection against the risk of remaining on the waiting list should be obtained at the time of candidate listing and again at the time of organ offer. In conclusion, there is insufficient evidence to recommend universal prospective screening of organ donors for HIV, HCV and HBV using current NAT platforms. Further study of viral screening modalities may reduce disease transmission risk without excessive donor loss.

Original languageEnglish
Pages (from-to)889-899
Number of pages11
JournalAmerican Journal of Transplantation
Volume10
Issue number4
DOIs
StatePublished - Apr 1 2010

Fingerprint

Nucleic Acids
Tissue Donors
HIV
Donor Selection
Waiting Lists
Infection
Blood Donors
Informed Consent
Transplantation

Keywords

  • Donor screening
  • Hepatitis B virus (HBV)
  • Hepatitis C virus
  • HIV
  • Nucleic acid diagnostics
  • Organ and tissue donation
  • Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Nucleic acid testing (NAT) of organ donors : Is the 'best' test the right test? a consensus conference report. / Humar, A.; Morris, Michele I; Blumberg, E.; Freeman, R.; Preiksaitis, J.; Kiberd, B.; Schweitzer, E.; Ganz, S.; Caliendo, A.; Orlowski, J. P.; Wilson, B.; Kotton, C.; Michaels, M.; Kleinman, S.; Geier, S.; Murphy, B.; Green, M.; Levi, M.; Knoll, G.; Segev, D.; Brubaker, S.; Hasz, R.; Lebovitz, D. J.; Mulligan, D.; O'Connor, K.; Pruett, T.; Mozes, M.; Lee, I.; Delmonico, F.; Fischer, S.

In: American Journal of Transplantation, Vol. 10, No. 4, 01.04.2010, p. 889-899.

Research output: Contribution to journalArticle

Humar, A, Morris, MI, Blumberg, E, Freeman, R, Preiksaitis, J, Kiberd, B, Schweitzer, E, Ganz, S, Caliendo, A, Orlowski, JP, Wilson, B, Kotton, C, Michaels, M, Kleinman, S, Geier, S, Murphy, B, Green, M, Levi, M, Knoll, G, Segev, D, Brubaker, S, Hasz, R, Lebovitz, DJ, Mulligan, D, O'Connor, K, Pruett, T, Mozes, M, Lee, I, Delmonico, F & Fischer, S 2010, 'Nucleic acid testing (NAT) of organ donors: Is the 'best' test the right test? a consensus conference report', American Journal of Transplantation, vol. 10, no. 4, pp. 889-899. https://doi.org/10.1111/j.1600-6143.2009.02992.x
Humar, A. ; Morris, Michele I ; Blumberg, E. ; Freeman, R. ; Preiksaitis, J. ; Kiberd, B. ; Schweitzer, E. ; Ganz, S. ; Caliendo, A. ; Orlowski, J. P. ; Wilson, B. ; Kotton, C. ; Michaels, M. ; Kleinman, S. ; Geier, S. ; Murphy, B. ; Green, M. ; Levi, M. ; Knoll, G. ; Segev, D. ; Brubaker, S. ; Hasz, R. ; Lebovitz, D. J. ; Mulligan, D. ; O'Connor, K. ; Pruett, T. ; Mozes, M. ; Lee, I. ; Delmonico, F. ; Fischer, S. / Nucleic acid testing (NAT) of organ donors : Is the 'best' test the right test? a consensus conference report. In: American Journal of Transplantation. 2010 ; Vol. 10, No. 4. pp. 889-899.
@article{1fca5b513774464794c11b505129e534,
title = "Nucleic acid testing (NAT) of organ donors: Is the 'best' test the right test? a consensus conference report",
abstract = "Nucleic acid testing (NAT) for HIV, HBV and HCV shortens the time between infection and detection by available testing. A group of experts was selected to develop recommendations for the use of NAT in the HIV/HBV/HCV screening of potential organ donors. The rapid turnaround times needed for donor testing and the risk of death while awaiting transplantation make organ donor screening different from screening blood-or tissue donors. In donors with no identified risk factors, there is insufficient evidence to recommend routine NAT, as the benefits of NAT may not outweigh the disadvantages of NAT especially when false-positive results can lead to loss of donor organs. For donors with identified behavioral risk factors, NAT should be considered to reduce the risk of transmission and increase organ utilization. Informed consent balancing the risks of donor-derived infection against the risk of remaining on the waiting list should be obtained at the time of candidate listing and again at the time of organ offer. In conclusion, there is insufficient evidence to recommend universal prospective screening of organ donors for HIV, HCV and HBV using current NAT platforms. Further study of viral screening modalities may reduce disease transmission risk without excessive donor loss.",
keywords = "Donor screening, Hepatitis B virus (HBV), Hepatitis C virus, HIV, Nucleic acid diagnostics, Organ and tissue donation, Transplantation",
author = "A. Humar and Morris, {Michele I} and E. Blumberg and R. Freeman and J. Preiksaitis and B. Kiberd and E. Schweitzer and S. Ganz and A. Caliendo and Orlowski, {J. P.} and B. Wilson and C. Kotton and M. Michaels and S. Kleinman and S. Geier and B. Murphy and M. Green and M. Levi and G. Knoll and D. Segev and S. Brubaker and R. Hasz and Lebovitz, {D. J.} and D. Mulligan and K. O'Connor and T. Pruett and M. Mozes and I. Lee and F. Delmonico and S. Fischer",
year = "2010",
month = "4",
day = "1",
doi = "10.1111/j.1600-6143.2009.02992.x",
language = "English",
volume = "10",
pages = "889--899",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Nucleic acid testing (NAT) of organ donors

T2 - Is the 'best' test the right test? a consensus conference report

AU - Humar, A.

AU - Morris, Michele I

AU - Blumberg, E.

AU - Freeman, R.

AU - Preiksaitis, J.

AU - Kiberd, B.

AU - Schweitzer, E.

AU - Ganz, S.

AU - Caliendo, A.

AU - Orlowski, J. P.

AU - Wilson, B.

AU - Kotton, C.

AU - Michaels, M.

AU - Kleinman, S.

AU - Geier, S.

AU - Murphy, B.

AU - Green, M.

AU - Levi, M.

AU - Knoll, G.

AU - Segev, D.

AU - Brubaker, S.

AU - Hasz, R.

AU - Lebovitz, D. J.

AU - Mulligan, D.

AU - O'Connor, K.

AU - Pruett, T.

AU - Mozes, M.

AU - Lee, I.

AU - Delmonico, F.

AU - Fischer, S.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Nucleic acid testing (NAT) for HIV, HBV and HCV shortens the time between infection and detection by available testing. A group of experts was selected to develop recommendations for the use of NAT in the HIV/HBV/HCV screening of potential organ donors. The rapid turnaround times needed for donor testing and the risk of death while awaiting transplantation make organ donor screening different from screening blood-or tissue donors. In donors with no identified risk factors, there is insufficient evidence to recommend routine NAT, as the benefits of NAT may not outweigh the disadvantages of NAT especially when false-positive results can lead to loss of donor organs. For donors with identified behavioral risk factors, NAT should be considered to reduce the risk of transmission and increase organ utilization. Informed consent balancing the risks of donor-derived infection against the risk of remaining on the waiting list should be obtained at the time of candidate listing and again at the time of organ offer. In conclusion, there is insufficient evidence to recommend universal prospective screening of organ donors for HIV, HCV and HBV using current NAT platforms. Further study of viral screening modalities may reduce disease transmission risk without excessive donor loss.

AB - Nucleic acid testing (NAT) for HIV, HBV and HCV shortens the time between infection and detection by available testing. A group of experts was selected to develop recommendations for the use of NAT in the HIV/HBV/HCV screening of potential organ donors. The rapid turnaround times needed for donor testing and the risk of death while awaiting transplantation make organ donor screening different from screening blood-or tissue donors. In donors with no identified risk factors, there is insufficient evidence to recommend routine NAT, as the benefits of NAT may not outweigh the disadvantages of NAT especially when false-positive results can lead to loss of donor organs. For donors with identified behavioral risk factors, NAT should be considered to reduce the risk of transmission and increase organ utilization. Informed consent balancing the risks of donor-derived infection against the risk of remaining on the waiting list should be obtained at the time of candidate listing and again at the time of organ offer. In conclusion, there is insufficient evidence to recommend universal prospective screening of organ donors for HIV, HCV and HBV using current NAT platforms. Further study of viral screening modalities may reduce disease transmission risk without excessive donor loss.

KW - Donor screening

KW - Hepatitis B virus (HBV)

KW - Hepatitis C virus

KW - HIV

KW - Nucleic acid diagnostics

KW - Organ and tissue donation

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=77949840641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949840641&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02992.x

DO - 10.1111/j.1600-6143.2009.02992.x

M3 - Article

VL - 10

SP - 889

EP - 899

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 4

ER -